Dataset opportunity
Adipogen — 工业运营数据集机会
Adipogen 持有的中等工业运营数据集，可用于工业监控和预测。
Score
67.3
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
授权
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球制药制造物联网支出市场 = 2024 年为 84.9 亿美元，复合年增长率为 10.3%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-11
AdipoGen PLXDC2 (human) ELISA Kit
labonline.com.au ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
工业运营数据集
Modality
时间序列
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
低（商品化）
Accessibility
开放/API
Legal
公司所有 — 可授权
Buyer persona
工业人工智能集成商
Adipogen 拥有一个宝贵的工业运营数据集，该数据集以时间序列数据的形式，来自其内部知识库和工业数据日志。这些数据捕获了试剂验证和蛋白质组学制造的科学和技术参数，使其直接适用于开发用于工业监控的高级人工智能模型，例如工艺优化和预测性质量控制。
商业价值巨大，因为制药制造中的物联网支出市场在 2024 年为84.9 亿美元，预计将以10.3% 的复合年增长率增长。[1] 尽管由于专有的研发日志，访问复杂，但该数据对于药物发现和蛋白质组学中的人工智能应用具有高价值，使其成为旨在提高制造效率和创新能力的买家的稀有战略资产。[1] ⚠ 尽职调查（有价值的数据，可协商的访问权限）：数据主要为科学和技术数据（试剂验证、化学性质）；专有的研发日志和实验结果可能存储在内部，未数字化以供外部销售；对于药物发现和蛋白质组学中的人工智能模型具有高价值 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Adipogen 拥有其复杂的生物制造和研究试剂生产线的运营数据。对于工业人工智能集成商而言，该数据集直接展示了高价值生物产品（如抗体和检测试剂盒）的复杂制造过程。这些时间序列数据对于开发工业监控和工艺优化模型至关重要，目标是蓬勃发展的 84.9 亿美元制药物联网市场，在该市场中效率和质量控制至关重要。
See dimension details ↓- Buyer Demand85
人工智能买家需求受到制药制造物联网市场强劲增长的推动，该市场正以 10.3% 的复合年增长率扩张，从而产生了对专业工业时间序列数据以优化生产的巨大需求。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility78
API/开放访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility80
低难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Dataset Specificity66
主导的“工业数据”，行业医疗保健，1 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity34
专有领域数据（开放降低了稀有度）
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/开放（当前）
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value64
适用于工业监控
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License92
所有权=公司所有，授权=干净
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据需求信号（0 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 超出已货币化的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Adipogen 是一个绝佳的目标，因为它是一家制造和销售生命科学试剂的上市公司，这意味着它可能持有其研发、生产和质量控制流程中作为核心运营业务副产品的有价值的休眠数据。
- Deep Qualification80
✓ 通过 — Adipogen 是一家试剂制造商，持有有价值的内部制造和质量控制数据。其数据转售权似乎不受公开条款的限制，使其成为一个合理的数据即产品机会。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
这些时间序列数据捕获了专业生物试剂（如抗体和检测试剂盒）生产的运营参数，为生物制药制造中的预测性维护和质量控制系统提供了宝贵的训练集。
Knowledge base / docs
知识库包含丰富的文本数据，详细介绍了所制造研究试剂的科学应用和特性，为人工智能模型理解工艺偏差及其对最终产品功效的影响提供了关键背景。
Data catalog / marketplace
数据目录提供了化学化合物和产品的结构化清单，由CAS 注册号标识，这对于构建制造环境的全面数字孪生至关重要。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Adipogen Industrial Operations — a Moderate industrial operations dataset (Time Series modality) in the healthcare domain. Primary AI use-case: Industrial Monitoring. Market signal: Global IoT Spending in Pharmaceutical Manufacturing Market = $8.49B in 2024, CAGR 10.3% (source: WiseGuyReports). [1]. Investment score 67.3/100 (confidence 0.49). Recommended action: License.
From the marketplace
Explore live data opportunities
Hydrostor — 工业传感器数据集机会
View opportunity →医疗保健Starseq — 医疗影像数据集机会
View opportunity →工业Pro Smoker — 工业运营数据集机会
View opportunity →